Harvard Bioscience, Inc.
HBIO
$0.3769
-$0.013-3.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -263.25% | -336.44% | -96.68% | -333.52% | 64.11% |
| Total Depreciation and Amortization | 2.27% | -0.11% | -2.74% | -5.24% | -7.62% |
| Total Amortization of Deferred Charges | 16.79% | 6.79% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 13.14% | 74.46% | 51.21% | 6,959.26% | 5,637.11% |
| Change in Net Operating Assets | -98.59% | -19.16% | 167.00% | 1,259.15% | 69.37% |
| Cash from Operations | -89.73% | -67.61% | 6.09% | 175.13% | 1,117.71% |
| Capital Expenditure | -47.87% | -165.97% | -77.01% | -64.48% | -12.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -100.00% | -100.00% | -- |
| Other Investing Activities | 348.57% | 522.60% | 1,286.11% | -- | -- |
| Cash from Investing | 25.29% | -99.28% | -21.20% | -178.22% | -13.14% |
| Total Debt Issued | 95.56% | 180.00% | 51.00% | -29.49% | -42.31% |
| Total Debt Repaid | 43.00% | 24.27% | -9.98% | -9.48% | -56.91% |
| Issuance of Common Stock | -59.14% | -55.50% | -59.76% | 29.38% | 61.18% |
| Repurchase of Common Stock | 77.13% | -133.66% | -64.05% | -88.15% | -54.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 98.92% | 73.11% | -1.61% | -76.79% | -327.71% |
| Foreign Exchange rate Adjustments | 56.25% | 108.21% | -6,650.00% | -993.44% | -742.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.22% | -493.37% | -524.62% | 128.35% | 93.21% |